Literature DB >> 9299482

Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein.

T Mori1, R H Shoemaker, R J Gulakowski, B L Krepps, J B McMahon, K R Gustafson, L K Pannell, M R Boyd.   

Abstract

Site-directed mutagenesis of DNA constructs coding for the novel, HIV-inactivating proteins cyanovirin-N (CV-N) and FLAG-cyanovirin-N (F-CV-N) was performed using mutagenic oligonucleotide primers in the polymerase chain reaction or by a restriction site elimination maneuver. The mutant constructs were expressed in Escherichia coli and the recombinant protein products were tested for binding to the HIV surface envelope glycoprotein gp 120 and for antiviral activity against infectious HIV. Results showed an overall very high correlation (r2 > 0.9) between the relative gp120 binding affinities and the anti-HIV activities of CV-N, F-CV-N, and the various mutants. An outlier, however, was a mutant which lacked one of the internal disulfide linkages normally present in CV-N and which showed modest gp120 binding but no antiviral activity against HIV. These findings are consistent with the view that gp120 binding is a necessary but not sufficient requirement for the HIV-inactivating activity of CV-N and related proteins; the sequence specificities for gp120 binding and anti-HIV activity are not identical.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299482     DOI: 10.1006/bbrc.1997.7202

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile.

Authors:  Dana Huskens; Geoffrey Férir; Kurt Vermeire; Jan-Christoph Kehr; Jan Balzarini; Elke Dittmann; Dominique Schols
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

2.  Designed oligomers of cyanovirin-N show enhanced HIV neutralization.

Authors:  Jennifer R Keeffe; Priyanthi N P Gnanapragasam; Sarah K Gillespie; John Yong; Pamela J Bjorkman; Stephen L Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-28       Impact factor: 11.205

3.  Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.

Authors:  Jan Balzarini; Kristel Van Laethem; Willy J Peumans; Els J M Van Damme; Anders Bolmstedt; Federico Gago; Dominique Schols
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Rational and computational design of stabilized variants of cyanovirin-N that retain affinity and specificity for glycan ligands.

Authors:  Vadim Patsalo; Daniel P Raleigh; David F Green
Journal:  Biochemistry       Date:  2011-11-16       Impact factor: 3.162

5.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

6.  Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.

Authors:  T Mori; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  1H, 13C, 15N resonance assignments and fold verification of a circular permuted variant of the potent HIV-inactivating protein cyanovirin-N.

Authors:  L G Barrientos; R Campos-Olivas; J M Louis; A Fiser; A Sali; A M Gronenborn
Journal:  J Biomol NMR       Date:  2001-03       Impact factor: 2.835

8.  Differential inhibitory effects of cyanovirin-N, griffithsin, and scytovirin on entry mediated by envelopes of gammaretroviruses and deltaretroviruses.

Authors:  Stig M R Jensen; Francis W Ruscetti; Alan Rein; Daniel C Bertolette; Carrie J Saucedo; Barry R O'Keefe; Kathryn S Jones
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  Cyanovirin-N produced in rice endosperm offers effective pre-exposure prophylaxis against HIV-1BaL infection in vitro.

Authors:  E Vamvaka; A Evans; K Ramessar; L R H Krumpe; R J Shattock; B R O'Keefe; P Christou; T Capell
Journal:  Plant Cell Rep       Date:  2016-03-23       Impact factor: 4.570

Review 10.  Bioactive Peptides Produced by Cyanobacteria of the Genus Nostoc: A Review.

Authors:  Anna Fidor; Robert Konkel; Hanna Mazur-Marzec
Journal:  Mar Drugs       Date:  2019-09-29       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.